

COG-UK HOCl Study Synopsis

Acronym	COG-UK Project <u>H</u> ospital- <u>O</u> nset <u>C</u> COVID-19 <u>I</u> nfections Study (COG-UK HOCl)
Formal Title	A phase III prospective, interventional, cohort, superiority study to evaluate the benefit of rapid COVID-19 genomic sequencing (the COVID-19 GENOMICS UK project) on infection control in preventing the spread of the virus in United Kingdom NHS hospitals.
Chief Investigator	Prof Judith Breuer
Sponsor	University College London (UCL)
Funding	COG-UK Consortium Grant (UKRI)

Study Design	Prospective, interventional, cohort, superiority study
Study Overview	<ul style="list-style-type: none"> - Site teams will be sequencing the viral genome of COVID-19 positive individuals with potential hospital-onset COVID-19 infection (HOCl) as part of the wider COG-UK sequencing project - Genomic sequencing reports for HOClS will be provided to Infection Prevention Control (IPC) teams at hospitals - COG-UK HOCl will evaluate the benefit of COVID-19 genomic sequencing and return of data report on infection control in preventing the spread of the virus in UK NHS hospitals.
Description of intervention	<p>Delivery of a COVID-19 genomic sequencing data report, either:</p> <ul style="list-style-type: none"> - within 48 hours from local sequencing hub to the NHS site's virology lab for dissemination to Infection Prevention and Control (IPC) teams; - or the same delivered within 5-10 days from centralised sequencing facility

Study sample size	2,000 patients with potential hospital-onset COVID-19 infection (HOClS)
--------------------------	---

Inclusion Criteria	<p>Individuals (inpatients) of any age that have been sampled for COG-UK will be eligible for COG-UK HOCl provided they have confirmed COVID-19 infection:</p> <ul style="list-style-type: none"> - Inpatients must be a potential hospital-onset COVID-19 infection (HOCl) <ul style="list-style-type: none"> o With confirmed test for COVID-19 >48 hours after admission o Not suspected to have COVID-19 at time of admission <p>Note: there are <u>no</u> exclusion criteria for COG-UK HOCl</p>
---------------------------	---

Primary Outcome Measure	<p>The contribution of viral sequencing to defining the occurrence and transmission location of HOClS</p> <p>Does the real-time (<48 hours) availability of COVID-19 sequence data:</p> <ul style="list-style-type: none"> - Reduce the incidence rate of IPC-defined HOClS compared with delayed (>4 days) and no sequence data. - Identify previously undetected nosocomial transmission in potential HOClS compared with delayed (>4 days) and no sequence data.
--------------------------------	--

Current Study Centres	Imperial Healthcare NHS Trust; Glasgow and Greater Clyde; Sheffield Teaching Hospitals Trust; Guys and St Thomas NHS Trust.
Key requirements for additional Study Centres	<ul style="list-style-type: none"> - NHS Trust with support from IPC team (usually DIPC or consultant); - Local rapid sequencing of SARS-CoV-2 virus sample capacity as part of COG-UK; - Bioinformatician within the sequencing team to support curation of sequence database for local samples - Senior clinical staff willing to be Principal Investigator; usually infectious diseases /IPC/Microbiology/virology consultant.

Contact details

Coordinating Centre

Comprehensive Clinical Trials Unit at University College London
 Institute of Clinical Trials & Methodology
 90 High Holborn, 2nd Floor
 London
 WC1V 6LJ

Chief Investigator	Clinical Project Manager	Trial Manager
Professor Judith Breuer	Mr James Blackstone	Dr Leanne Hockey
Tel: 0203 108 2130	Tel: 0203 108 6584	Tel: 0203 108 5970
Email: j.breuer@ucl.ac.uk	Email: j.blackstone@ucl.ac.uk	Email: l.hockey@ucl.ac.uk

Shared inbox should be used for all trial-specific queries: cctu.hoci@ucl.ac.uk